IRWD - アイアンウッド・ファ―マシュ―ティカルズ (Ironwood Pharmaceuticals Inc.)

IRWDのニュース

   Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment  2020/09/29 11:15:00 Business Wire
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that data from IW-3718-302, one of Ironwood’s two identical Phase III trials evaluating IW-3718 in refractory gastroesophageal reflux disease (GERD), did not meet the pre-specified criteria associated with a planned early efficacy assessment. Following the assessment from an independent data monitoring committee, Ironwood unblinded the data and confirmed that IW-3718-302 did
   Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences  2020/09/02 20:00:00 Business Wire
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will participate in fireside chats at two upcoming virtual investor conferences in September: 2020 Wells Fargo Virtual Healthcare Conference on Wednesday, September 9, 2020 at 11:20 a.m. ET Morgan Stanley Virtual 18th Annual Global Healthcare Conference on Monday, September 14, 2020 at 9:00 a.m. ET A live webcast of Ironwood’s fireside chats will be accessible through the Investors section of the company’s website at www.iro
   Ironwood Pharmaceuticals Reports Second Quarter 2020 Results; Delivered GAAP Net Income of $25 Million and Adjusted EBITDA of $33 Million  2020/08/06 11:00:00 Business Wire
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided an update on its second quarter 2020 results and recent business performance, as well as an update related to the impact of the COVID-19 pandemic on its business. “Strong execution resulted in another solid quarter, highlighting the fundamental strength and resiliency of our business as we continue to advance our mission of advancing GI diseases and redefining the standard of
   Ironwood Pharmaceuticals to Host Second Quarter 2020 Investor Update Call  2020/07/23 20:05:00 Business Wire
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its second quarter 2020 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 6, 2020. Individuals interested in participating in the call should dial (866) 324-3683 (U.S. and Canada) or (509) 844-0959 (international) using conference ID number and event passcode 6183913. To access the webcast, please visit the Investors section of Ironwood’s website at www.iro
   Hedge Funds Still Bullish On Ironwood Pharmaceuticals, Inc. (IRWD)  2020/06/06 17:44:50 Yahoo Finance
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary
   Ironwood Pharmaceuticals Provides Update on Impact of COVID-19  2020/03/26 13:00:00 Business Wire
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today provided an update on certain impacts of COVID-19 on its business and the actions it is taking to mitigate the spread of this virus and help protect the safety and well-being of its employees, healthcare providers, patients and broader communities. “In the face of the COVID-19 pandemic, we are taking important steps in an effort to help slow the spread of this virus, prioritize the hea
   Ironwood (IRWD) Down 22.1% Since Last Earnings Report: Can It Rebound?  2020/03/14 15:30:47 Zacks Investment Research
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Ironwood (IRWD) Surpasses Q4 Earnings and Sales Estimates  2020/02/14 14:50:00 Zacks Investment Research
Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter as well. Stock up.
   Ironwood Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2019 Results, Exceeding Full Year 2019 Guidance; Provides Full Year 2020 Guidance  2020/02/13 12:00:00 Business Wire
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided an update on its fourth quarter and full year 2019 results and recent business performance. “2019 brought us a catalyzing opportunity to become a GI-focused healthcare company dedicated to advancing the treatment of GI diseases and redefining the standard of care for millions of patients,” said Mark Mallon, chief executive officer of Ironwood. “To do this, we are executing on
   What's in Store for Ironwood (IRWD) This Earnings Season?  2020/02/10 15:13:00 Zacks Investment Research
Ironwood Pharmaceuticals' (IRWD) Linzess is likely to have driven total revenues in the fourth quarter.
   Ironwood (IRWD) Down 22.1% Since Last Earnings Report: Can It Rebound?  2020/03/14 15:30:47 Zacks Investment Research
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Ironwood (IRWD) Surpasses Q4 Earnings and Sales Estimates  2020/02/14 14:50:00 Zacks Investment Research
Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter as well. Stock up.
   Ironwood Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2019 Results, Exceeding Full Year 2019 Guidance; Provides Full Year 2020 Guidance  2020/02/13 12:00:00 Business Wire
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided an update on its fourth quarter and full year 2019 results and recent business performance. “2019 brought us a catalyzing opportunity to become a GI-focused healthcare company dedicated to advancing the treatment of GI diseases and redefining the standard of care for millions of patients,” said Mark Mallon, chief executive officer of Ironwood. “To do this, we are executing on
   What's in Store for Ironwood (IRWD) This Earnings Season?  2020/02/10 15:13:00 Zacks Investment Research
Ironwood Pharmaceuticals' (IRWD) Linzess is likely to have driven total revenues in the fourth quarter.
   Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: Should You Buy?  2020/02/06 17:31:01 Zacks Investment Research
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

calendar